ArticleTalanta2022
Chemometric analysis of the global pattern of volatile organic compounds in the exhaled breath of patients with COVID-19, post-COVID and healthy subjects. Proof of concept for post-COVID assessment.
Article in Talanta, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06402318 (A Prospective, Non-interventional, Observational Clinical Validation Study to Analytically Validate the A&M Breathalyzer PROTECT Kiosk Breath Capture System.), which is not on this map. Cited by 12 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective, Non-interventional, Observational Clinical Validation Study to Analytically Validate the A&M Breathalyzer PROTECT Kiosk Breath Capture System.
Who cites it
12 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Exhaled Volatile Organic Compounds Detection in Pneumonia Screening: A Comprehensive Meta-analysis.Lung · 2024Pooled it
- A comprehensive meta-analysis and systematic review of breath analysis in detection of COVID-19 through Volatile organic compounds.Diagnostic microbiology and infectious disease · 2024Pooled it
- Accuracy of the Electronic Nose Breath Tests in Clinical Application: A Systematic Review and Meta-Analysis.Biosensors · 2021Pooled it
- A Review on Long COVID Screening: Challenges and Perspectives Focusing on Exhaled Breath Gas Sensing.ACS sensors · 2025Review
- Enhanced real-time mass spectrometry breath analysis for the diagnosis of COVID-19.ERJ open research · 2023Article
- Diagnostic performance of eNose technology in COVID-19 patients after hospitalization.BMC pulmonary medicine · 2023Article
- Breath analysis by ultra-sensitive broadband laser spectroscopy detects SARS-CoV-2 infection.Journal of breath research · 2023Article
- Potential for Early Noninvasive COVID-19 Detection Using Electronic-Nose Technologies and Disease-Specific VOC Metabolic Biomarkers.Sensors (Basel, Switzerland) · 2023Review
- Predominant SARS-CoV-2 variant impacts accuracy when screening for infection using exhaled breath vapor.Communications medicine · 2022Article
- AuNP-based biosensors for the diagnosis of pathogenic human coronaviruses: COVID-19 pandemic developments.Analytical and bioanalytical chemistry · 2022Review
- An Experimental Apparatus for E-Nose Breath Analysis in Respiratory Failure Patients.Diagnostics (Basel, Switzerland) · 2022Article
- Expert considerations and consensus for using dogs to detect human SARS-CoV-2-infections.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this research was to evaluate the application of an electronic nose and chemometric analysis to discriminate volatile organic compounds between patients with COVID-19, post-COVID syndrome and controls in exhaled breath samples. A cross-sectional study was performed on 102 exhaled breath samples, 42 with COVID-19, 30 with the post-COVID syndrome and 30 control subjects. Breath-print analysis was performed by the Cyranose 320 electronic nose with 32 sensors. Group data were evaluated by Principal Component Analysis (PCA), Canonical Discriminant Analysis (CDA), and Support Vector Machine (SVM), and the test's diagnostic power was evaluated through a Receiver Operaring Characteristic curve(ROC curve). The results of the chemometric analysis indicate in the PCA a 97.6% (PC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.